Understand how we got here — and how to move forward.


Ready-to-Use Slides

Making the case for an incidental pulmonary nodules management program


    These slides are designed to help health system leaders facilitate discussions with internal stakeholders about the value of adding an incidental pulmonary nodule program to your organizations lung cancer detection program. This resource provides research-based, customizable slides to help identify opportunity areas and investment considerations.

    About the sponsor

    The Lung Ambition Alliance, a global coalition with partners across disciplines in over 50 countries, was formed to combat lung cancer through accelerating innovation and driving forward meaningful improvements for people with lung cancer. We do this by advocating for improved approaches in three areas: screening and early diagnosis, accelerated delivery of innovative medicine, and improved quality care.

    Learn more about the Lung Ambition Alliance

    This report is sponsored by AstraZeneca, an Advisory Board member organization. Representatives of AstraZeneca helped select the topics and issues addressed. Advisory Board experts wrote the report, maintained final editorial approval, and conducted the underlying research independently and objectively. Advisory Board does not endorse any company, organization, product or brand mentioned herein.

    To learn more, view our editorial guidelines

    Have a Question?


    Ask our experts a question on any topic in health care by visiting our member portal, AskAdvisory.